Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cystic Fibrosis: Management01:24

Cystic Fibrosis: Management

144
Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic...
144
Drugs for Treatment of Constipation-Predominant IBS01:21

Drugs for Treatment of Constipation-Predominant IBS

140
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
140
Cystic Fibrosis: Pathogenesis01:23

Cystic Fibrosis: Pathogenesis

194
Cystic fibrosis (CF), an autosomal recessive disorder, significantly affects the function of exocrine glands. This genetically inherited disease is characterized by the production of thick and sticky mucus, which can severely affect various organs and systems in the body.
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation,...
194
Assessment of the Rectum and Anus01:25

Assessment of the Rectum and Anus

165
Evaluating the rectum and anus plays a crucial role in conducting a thorough physical examination of the gastrointestinal system. Although it may be uncomfortable and often embarrassing for the patient, it holds immense diagnostic value, particularly in detecting gastrointestinal diseases and abnormalities. This guide will explain how to perform this assessment using inspection and palpation methods.
Rectal Inspection
Begin by inspecting the perianal and anal areas for color, texture, rashes,...
165
Drugs for Treatment of Diarrhea-Predominant IBS01:17

Drugs for Treatment of Diarrhea-Predominant IBS

151
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
151
Drugs Affecting GI Tract Motility: Bulk-Forming and Stimulant Laxatives01:22

Drugs Affecting GI Tract Motility: Bulk-Forming and Stimulant Laxatives

186
Laxatives enhance bowel movements and alleviate constipation. They augment the stool's bulk, stimulate intestinal muscle contractions, draw water into the intestines, or soften the stool. There are five key types of laxatives: bulk laxatives, stimulant laxatives, osmotic laxatives, stool softeners, and lubricant laxatives.
Bulk-forming laxatives, such as psyllium, methylcellulose, and polycarbophil, absorb water in the intestine, increasing stool bulk and promoting bowel movement. This...
186

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Access to inpatient video-EEG monitoring for patients with frequent seizure-related emergency visits.

Epilepsy research·2026
Same author

Food Insecurity and Gastrointestinal Health: Examining Links Between Food Security, Constipation, and Diarrhea in the National Health and Nutrition Examination Survey.

Digestive diseases and sciences·2026
Same author

IBD Care Across Diverse Patient Populations: Changing the Narrative.

Digestive diseases and sciences·2026
Same author

Polymyxin B haemoadsorption in endotoxic septic shock (Tigris): a multicentre, open-label, Bayesian, randomised, controlled, phase 3 trial.

The Lancet. Respiratory medicine·2026
Same author

Percutaneous endoscopic gastrostomy-assisted placement of endoluminal vacuum-assisted closure for esophageal perforation.

Endoscopy·2026
Same author

Characterizing Barriers to Engaging in Digestive Health care for Sexual and Gender Minority People in the United States.

Clinical and translational gastroenterology·2026

Related Experiment Video

Updated: Jun 12, 2025

Forskolin-induced Swelling in Intestinal Organoids: An In Vitro Assay for Assessing Drug Response in Cystic Fibrosis Patients
07:04

Forskolin-induced Swelling in Intestinal Organoids: An In Vitro Assay for Assessing Drug Response in Cystic Fibrosis Patients

Published on: February 11, 2017

19.2K

Constipation is Associated With Increased Hospital Utilization in Cystic Fibrosis: A National Inpatient Sample

Matt Pelton1, Arvind Bussetty1, Sarah Abdel-Meguid1

  • 1Internal Medicine, Rutgers Robert Wood Johnson, New Brunswick, New Jersey.

Gastro Hep Advances
|June 9, 2025
PubMed
Summary

Constipation in patients with cystic fibrosis (CF) significantly increases hospital stays and healthcare costs. This effect is more pronounced in CF patients with pancreatic insufficiency.

Keywords:
ConstipationCystic FibrosisDistal Intestinal Obstruction SyndromeGenderPancreatic Insufficiency

More Related Videos

The WinCF Model - An Inexpensive and Tractable Microcosm of a Mucus Plugged Bronchiole to Study the Microbiology of Lung Infections
06:57

The WinCF Model - An Inexpensive and Tractable Microcosm of a Mucus Plugged Bronchiole to Study the Microbiology of Lung Infections

Published on: May 8, 2017

9.2K
Rectal Organoid Morphology Analysis ROMA: A Diagnostic Assay in Cystic Fibrosis
07:56

Rectal Organoid Morphology Analysis ROMA: A Diagnostic Assay in Cystic Fibrosis

Published on: June 10, 2022

2.8K

Related Experiment Videos

Last Updated: Jun 12, 2025

Forskolin-induced Swelling in Intestinal Organoids: An In Vitro Assay for Assessing Drug Response in Cystic Fibrosis Patients
07:04

Forskolin-induced Swelling in Intestinal Organoids: An In Vitro Assay for Assessing Drug Response in Cystic Fibrosis Patients

Published on: February 11, 2017

19.2K
The WinCF Model - An Inexpensive and Tractable Microcosm of a Mucus Plugged Bronchiole to Study the Microbiology of Lung Infections
06:57

The WinCF Model - An Inexpensive and Tractable Microcosm of a Mucus Plugged Bronchiole to Study the Microbiology of Lung Infections

Published on: May 8, 2017

9.2K
Rectal Organoid Morphology Analysis ROMA: A Diagnostic Assay in Cystic Fibrosis
07:56

Rectal Organoid Morphology Analysis ROMA: A Diagnostic Assay in Cystic Fibrosis

Published on: June 10, 2022

2.8K

Area of Science:

  • Gastroenterology
  • Pulmonology
  • Health Economics

Background:

  • Constipation is a common and debilitating symptom for patients with cystic fibrosis (CF).
  • Severe constipation can lead to distal intestinal obstruction syndrome in CF patients.
  • Understanding the impact of constipation on hospitalization outcomes is crucial for patient care.

Purpose of the Study:

  • To characterize the relationship between constipation during hospitalization and its associated symptoms, complications, and healthcare costs in patients with CF.
  • To compare hospitalization outcomes for patients with CF and constipation versus those without.
  • To analyze the impact of constipation on length of stay and total charges in hospitalized CF patients.

Main Methods:

  • Utilized the National Inpatient Sample database for discharges from 2015-2019.
  • Matched hospitalized patients with CF to the general population based on comorbidity index, hospitalization severity, and demographics.
  • Created cohorts with and without comorbid constipation for comparative analysis, adjusting for relevant covariates.

Main Results:

  • Constipation was present in 14.0% of hospitalized patients with CF, compared to 5.6% in the general population.
  • Constipation was independently associated with a 1.22-day increase in length of stay and $14,280 in additional charges for CF patients.
  • The association of higher costs with constipation was significantly greater in CF patients with pancreatic insufficiency.

Conclusions:

  • Comorbid constipation in hospitalized patients with CF is independently linked to increased length of stay and healthcare expenditures.
  • The economic burden of constipation is exacerbated in CF patients with pancreatic insufficiency.
  • These findings highlight the importance of managing constipation in hospitalized CF patients to mitigate adverse outcomes and reduce costs.